HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 08-15-2005, 12:45 PM   #1
Rich
Guest
 
Posts: n/a
Lapatinib, which Garnier calls “an exquisitely designed drug” meant to treat tumors related to breast cancer, was originally put on a fast track by the FDA, and the company was expected to submit it for market approval this year. But Glaxo backtracked in May after receiving disappointing trial data. Now the drug may not be submitted for FDA approval until late this decade, according to some estimates.

http://www.financialexpress.com/fe_full_st...ontent_id=99139
  Reply With Quote
Old 09-13-2005, 06:23 AM   #2
Tom
Guest
 
Posts: n/a
Hi Rich. I have been watching the lapatinib situation for some time now, and I am concerned about it's true potential as well. However, you must realize that reporting about such things by financial institutions is a little different than that of the medical field, and particularly unusual when it originates from overseas.

I was an active stock trader some years ago, and was used to the need to dig deeper for the truth about promising new drugs. I have a friend that works for one drug company (not GSK) that can help me find the true scuttlebut on lapatinib with a little work. I will let you know what I find out as soon as I have some concrete evidence. Keep your hopes up, as do I. Lapatinib, if it does half of what is claimed, could do great things for cancer treatment. The drug truly IS exquisitely designed, as it approaches the cancer riddle through two different mechanisms of action. Take care.
  Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 07:47 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter